Eli Lilly & Co. is asking people who took copies of its blockbuster weight loss drug to give the company access to their ...

Pharmaceutical company Eli Lilly warning in an open letter on Thursday about the dangers of fake and compounded versions of its diabetes and weight loss medications Mounjaro and Zepbound.

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 586.36% and ...

“I am gobsmacked that Lilly is seeking confidential patient medical records to build a case against the very therapies that ...

Eli Lilly (NYSE: LLY), the developer of Mounjaro, has proven that it can compete with Novo Nordisk at a high level. Moreover, the company's sibling treatment to Mounjaro -- Zepbound -- has gotten ...

One of the highlights of Eli Lilly's third-quarter results ... Lilly's head of diabetes, Mike Mason, said on the company's results call that the rollout of Mounjaro (tirzepatide) was "really ...

Eli Lilly’s stock has climbed almost 60% this year and trades for more than $900. The pharma giant also has seen soaring ...

Eli Lilly and Company LLY reported second-quarter 2024 ... Higher volumes of drugs like Mounjaro, Zepbound, Verzenio and ...

Although women lost more weight, all participants saw significant decreases in total body weight on all doses of the medication.

Eli Lilly and Company (NYSE: LLY ... evaluating the efficacy and safety of tirzepatide (Zepbound® and Mounjaro®) once weekly for long-term weight management and delay in progression to diabetes ...